Insulin glargine
Also known as: Lantus · Toujeo (previously Optisulin) · Abasaglar (previously Abasria) · Semglee · Ondibta · BASAGLAR KwikPen · Insulin glargine U-300 · Insulin glargine U-300 Max · LANTUS SOLOSTAR · TOUJEO
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents, and children aged two years and above, or from the age of six years depending on the specific product. In the United States, it is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The limitations of use in the United States specify that it is not for the treatment of diabetic ketoacidosis.
From: Source: European Medicines Agency (EMA), Lantus — EPAR, 05/03/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Toujeo (previously Optisulin) — EPAR, 05/03/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 274783 insulin glargine
- EMA
- EMEA/H/C/000284, EMEA/H/C/000309, EMEA/H/C/002835, EMEA/H/C/004280, EMEA/H/C/006136
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
FDA (USA) BASAGLAR KwikPen
1 INDICATIONS AND USAGE BASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for treating diabetic ketoacidosis. ( 1 ) Limitations of Use BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.
Data provided by the U.S. Food and Drug Administration.
Document date: 20260616 · Official document →
EMA (EU) Lantus
Treatment of diabetes mellitus in adults, adolescents and children aged two years and above
Source: European Medicines Agency (EMA), Lantus — EPAR, 05/03/2026. © European Medicines Agency.
Document date: 05/03/2026 · Official document →
EMA (EU) Toujeo (previously Optisulin)
Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.
Source: European Medicines Agency (EMA), Toujeo (previously Optisulin) — EPAR, 05/03/2026. © European Medicines Agency.
Document date: 05/03/2026 · Official document →
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Insulin glargine approved for in the European Union?
Treatment of diabetes mellitus in adults, adolescents and children aged two years and above (Source: European Medicines Agency (EMA), Lantus — EPAR, 05/03/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Lantus — EPAR, 05/03/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Toujeo (previously Optisulin) — EPAR, 05/03/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.